Beijing Memorial Pharmaceutical Research and Development Co.,Ltd.
+86 15810288723
Lang. :
English
中 文
☰
Home
Main Business
International Purchasement of Comparator
Exportation of R&D Drugs
Comparator Import & Export
Storage and Logistics of Investigational Product
Repackage of The Investigational Product
Clinical Trial Subjects Recruitment
RLD
R&D Products
News
Latest News
NDA News
Clinical News
Industrial News
Company Update
About Us
About CliniExpert
Big Events
Photo Wall
Clinical Viewpoint
Talent Recruitment
Home
News
· R&D Products
Olmesartan Medoxomil and Hydrochlorothiazide Tablets
CliniExpert
•
2019/12/20
150
•
0
奥美沙坦酯氢氯噻嗪片
Return
Hot Info
FDA Approves Ryzneuta (efbemalenograstim alfa) for Chemotherapy-Induced Neutropenia
FDA Approves DefenCath (taurolidine and heparin) to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients
FDA Approves Augtyro (repotrectinib) for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
FDA Approves Adzynma (ADAMTS13, recombinant-krhn) Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
FDA Approves Ixchiq (Chikungunya Vaccine, Live) for the Prevention of Disease Caused by Chikungunya Virus
FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
FDA Approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the Treatment of H. pylori Infection in Adults
FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
PellePharm Completes Enrollment Of Pivotal Phase 3 Clinical Trial Of Patidegib Topical Gel In Patients With Gorlin Syndrome
Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine
The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors
15810288723
